Objectif "Actinomycetes produce a wealth of important natural products, which play a pivotal role in modern drug-based therapy of various diseases. Recent whole-genome sequencing projects have revealed that the number of biosynthetic gene clusters significantly outnumbers the natural products produced by actinomycetes under laboratory conditions. Only a minority of biosynthetic gene clusters are expressed under known laboratory conditions. The major challenge in the field now is to exploit this untapped reservoir of potentially active and useful compounds. Using synthetic and system biology approaches we will access these so far unavailable natural products.The overall strategy of the EXPLOGEN project will be implemented through the activities of four different work packages.WP1. Synthetic biobricks. Construction of different synthetic biobricks, which can be mixed and matched to build the synthetic devices and systems in actinomycetes. Generation of streptomyces strains with minimized genomes.WP2. Systems biology. The metabolic reconstruction of Streptomyces albus and S. lividans and its simulation in order to deliver gene targets for knockouts and overexpression experiments. Predicted mutants should accumulate main precursors of natural products, particularly polyketides.WP3. Regulatory network identification. Using systematic in vivo transposon mutagenesis combined with GFP-based flow cytometry assay and gusA based screening, we will identify gene networks responsible for the regulation and “silencing” of natural product biosynthesis.WP4. Metabolic engineering of the hosts. Generation of S. albus and S. lividans hosts accumulating main precursors for the heterologous production of natural products. Heterologous expression of the aranciamycin, phenalinolactone, and two ""cryptic"" biosynthetic gene clusters in the developed hosts.The outcome of this project will be a new platform for the production of novel natural products including valuable pharmaceuticals." Champ scientifique engineering and technologyindustrial biotechnologymetabolic engineeringmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsnatural sciencesbiological sciencesgeneticsgenomes Programme(s) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Thème(s) ERC-SG-LS9 - ERC Starting Grant - Applied life sciences and biotechnology Appel à propositions ERC-2011-StG_20101109 Voir d’autres projets de cet appel Régime de financement ERC-SG - ERC Starting Grant Institution d’accueil HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH Contribution de l’UE € 1 484 016,00 Adresse INHOFFENSTRASSE 7 38124 Braunschweig Allemagne Voir sur la carte Région Niedersachsen Braunschweig Braunschweig, Kreisfreie Stadt Type d’activité Research Organisations Chercheur principal Andriy Luzhetskyy (Dr.) Contact administratif Michael Strätz (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Bénéficiaires (1) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH Allemagne Contribution de l’UE € 1 484 016,00 Adresse INHOFFENSTRASSE 7 38124 Braunschweig Voir sur la carte Région Niedersachsen Braunschweig Braunschweig, Kreisfreie Stadt Type d’activité Research Organisations Chercheur principal Andriy Luzhetskyy (Dr.) Contact administratif Michael Strätz (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée